Health Economics›Small cell lung cancer›Relapsed or refractory disease subsequent lines

Relapsed or refractory disease subsequent lines

Small cell lung cancer · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Epirubicin and Ifosfamide Variant #03	—	R 27 105	21d	—	—	—	—	—
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	~3.8 mo	~6.6 mo	~3	~R 42 639 PFS proxy · indirect	7
Topotecan monotherapy Variant #01	—	R 11 563	21d	2.7 mo	8.3 mo	4	R 46 253 PFS proxy	8
Ifosfamide monotherapy N/A - secondary systemic drug	—	R 9 835	28d	~4.0 mo	~8.4 mo	~5	~R 49 173 PFS proxy · indirect	2
Temozolomide monotherapy Variant #13	—	R 8 153	28d	~4.0 mo	~16.3 mo	~5	~R 40 764 PFS proxy · indirect	10
Bendamustine monotherapy Variant #01	—	R 5 419	—	~16.5 mo	—	—	—	2
Cisplatin and Etoposide (EP) Variant #01	—	R 4 264	42d	~5.0 mo	~10.2 mo	~4	~R 17 056 PFS proxy · indirect	10
Etoposide monotherapy Variant #01	—	R 2 872	28d	—	—	—	—	—
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	—	~6.8 mo	—	—	2
Ifosfamide and Paclitaxel N/A - secondary systemic drug	—	R 1 375	21d	—	~21.3 mo	—	—	2
CAV Variant #01	—	R 760	21d	—	7.6 mo	—	—	1
Vinorelbine monotherapy Variant #01	—	R 583	21d	—	~6.3 mo	—	—	4
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	~3.2 mo	~9.8 mo	~4	~R 973 PFS proxy · indirect	52
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	—	7.0 mo	—	—	—
Tarlatamab monotherapy Variant #01 Partial	—	—	14d	—	13.6 mo	—	—	—

15 of 15 regimens shown